Evidence map›Paper›PMID 33777758›Full record

ArticleFrontiers in oncology2021

Outcomes After Accelerated Partial Breast Irradiation in Women With Triple Negative Subtype and Other "High Risk" Variables Categorized as Cautionary in The ASTRO Guidelines.

Anabel Goulding, Lina Asmar, Yunfei Wang, Shannon Tole, Lora Barke, Jodi Widner, Charles Leonard

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01185132 phase3recruitingnot on this map

A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy

TypeinterventionalSponsorRocky Mountain Cancer CentersRan2009 to 2028Enrolled660ConditionsBreast CancerArmsaccelerated partial breast irradiation - 3D-conformal planning, accelerated partial breast irradiation - IMRT planning
NCT01185145 phase2unknown statusnot on this map

A Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy

TypeinterventionalSponsorRocky Mountain Cancer CentersRan2004 to 2024Enrolled291ConditionsBreast CancerArmsBreast Brachytherapy with Mammosite RTS, Intensity Modulated Radiotherapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anabel GouldingRadiation Oncology, Rocky Mountain Cancer Centers, Denver, CO, United States.
Lina AsmarStatistics, Linasmar Consulting, Houston, TX, United States.
Yunfei WangStatistics, Linasmar Consulting, Houston, TX, United States.
Shannon ToleRadiation Oncology, Rocky Mountain Cancer Centers, Denver, CO, United States.
Lora BarkeRadiology, Invision Sally Jobe, Greenwood Village, CO, United States.
Jodi WidnerSurgery, SurgOne, Greenwood Village, CO, United States.
Charles LeonardRadiation Oncology, Rocky Mountain Cancer Centers, Denver, CO, United States.
Rocky Mountain Cancer Centers · USInvision Sally Jobe · USTri-County Health Department · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report a primary objective clinical outcome of ipsilateral breast recurrence following accelerated partial breast irradiation (APBI) in women with triple negative and other high risk breast cancer (as described in 2017 ASTRO guidelines) (i.e., age 40-49, size 2.1-3.0 cm, estrogen receptor negative and invasive lobular breast cancer). Secondary objectives of axillary and regional failure as well as overall survival are also reported. METHODS AND MATERIAL: Patients from two clinical trials (NCT01185145, NCT01185132) were treated with 38.5 Gy IMRT or 3D-CRT APBI w/3.85 Gy fraction/BID fractionation for 10 fractions. Triple negative and other high risk patients (n=269) were compared to a total of 478 low risk patients which ASTRO defined as "suitable" for APBI. High risk patients, for the purpose of this study, were defined as those who possess one or more high risk criteria: triple negative (n=30), tumor size >2 cm <3 cm (n=50), HER 2+ (n=54), age range 40-50 years (n=120), ER- (n=43), and ILC histology (n=52).

resultsMedian follow up was 4.0 years for all patients. No significant difference was found for this high-risk cohort at 5 years for ipsilateral breast, or regional recurrences. Axillary recurrence was significantly adversely impacted by triple negative and ER- statuses (p=0.01, p=0.04). There were significant correlations between triple negative type and axillary recurrence on multivariate analysis (p=0.03). Overall survival for all patients was unaffected by any of the high-risk categories.

conclusionThe data from this study suggests that women possessing high risk features are at no more meaningful risk for recurrence than other patients considered to be acceptable for APBI treatment. However, the finding of axillary recurrence in patients with triple negative breast cancer does warrant a degree of caution in proceeding with accelerated partial breast irradiation technique in this patient group.

Indexed as

estrogen receptor negative breast cancerHER2 breast cancer +infiltrating lobular breast cancerpartial breast external beam radiotherapytriple negative breast canceryoung age group

Identifiers

PMID33777758
PMCPMC7993056
OpenAlexW3137393722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.